Amplified Sciences
Earlier detection of debilitating disease.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | $2.6m | Seed | |
| Total Funding | 000k | ||
Related Content
Amplified Sciences is a pioneering company in the field of diagnostic testing, focusing on the early detection, risk stratification, and monitoring of challenging diseases. The company serves healthcare providers and clinicians who require advanced diagnostic tools to improve patient outcomes. Operating within the medical diagnostics market, Amplified Sciences leverages its proprietary ultra-sensitive universal optical reporter platform technology to develop multi-omics diagnostic tests. One of their flagship products, the PanCystPro test, is designed to assist clinicians in the risk stratification of patients with pancreatic cystic lesions by detecting multiple biomarkers in small fluid volumes. The business model revolves around the development and commercialization of these innovative diagnostic tests, generating revenue through the sale of test kits and related services.
Keywords: diagnostic tests, early detection, risk stratification, monitoring, challenging diseases, multi-omics, biomarkers, PanCystPro, healthcare providers, proprietary technology.